Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide

Fig. 2

Clonogenic clones surviving 500 μM TMZ treatment showed a delay in tumor formation compared to those of unselected parental GSC. a. Kaplan-Meier survival curves of indicated GSC-parental (5 mice/group) and GSC-500 μM TMZ (5 mice/group). P-values were calculated using the Log-rank test. The survival curves were plotted for individual (ac) and combined 3 GSC (d). b. Representative macrophotographic image of glioma xenografts initiated by GSC-parental and GSC-500 μM TMZ that are growing in the intracranial site. c. Representative hematoxylin and eosin (HE) staining of xenograft tumors. Brain tissues from mice injected with either GSC-parental (D431, S496, E445) or GSC-500 μM TMZ (D431, S496, E445) display invasive growth of gliomas and exhibit histopathological features of human glioblastoma, including hypercellularity (a, h), hyperchromatism (b, i), pleomorphism and mitosis (ce, jl), vascular endothelial hyperplasia (f, m), oligodendroglial components (g, n), and chondrocytic components (o)

Back to article page